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Targeted immune checkpoint-based immunotherapy has achieved 
remarkable success in the treatment of malignant tumors. Immune 
checkpoint inhibitor-programmed cell death protein 1 (PD-1) antibody 
opens a new era of immunotherapy for platinum-refractory recurrent/
metastatic oral squamous cell carcinoma (OSCC). The overall survival of 
patients treated with immunological checkpoint inhibitors was significantly 
prolonged, and the overall incidence of grade 3-4 drug-related adverse 
events (AEs) occurred was lower; however, there are still some challenges 
to the PD-1’s application in OSCC clinic treatment. This article is just to 
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common malignant tumor category worldwide. Oral carcinoma, the most 
common subcategory of HNSCC, can be the 9th - if alone 
- on the same ranking list. Each year, more than 300,000 
people are affected by oral carcinoma, in which OSCC 
accounts for 90%. At present, the treatment of OSCC 
mainly consists of traditional surgery, radiotherapy and 
chemotherapy. More than 50% of OSCC patients have 
tumor recurrence or metastasis within 3 years; and more 
than 145,000 patients die from oral malignant tumors each 
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year. The recorded 5-year survival rate is about 50% [1-4].
In recent years, with the development of research 
on the relationship between immunity and tumor, 
immunotherapy has become an important means of tumor 
therapy further to traditional surgery, radiotherapy and 
chemotherapy. In 2018, Prof. Allison and Prof. Honio 
won the Nobel Prize in Physiology or Medicine for 
their research work on cytotoxic T lymphoid-associated 
antigen-4 (CTLA-4) and PD-1 in the immune checkpoint. 
Since 2010, the immunosuppressive checkpoint molecules 
have been recognized as new targets for immunotherapy, 
whose curative effectiveness was initially demonstrated 
in treatment of advanced melanoma and then gradually 
applied to different types of malignancies with varying 
degrees of benefit. In the second half of 2016, two PD-1 
immune checkpoint inhibitors, Nivolumab (Opdivo) 
and Pembrolizumab (Keytruda), were approved by the 
FDA for treating relapsed and refractory HNSCC. This 
means currently there are two PD-1 immune checkpoint 
inhibitors approved for treating OSCC. According to the 
current research progress, compared with the traditional 
treatment, PD-1 immunocheckpoint inhibitor has better 
prospect on treatment of advanced OSCC.
2. Immune Checkpoint Protein
As the core executor in the process of anti-tumor 
immunity, T cells have two types of stimulation signal 
molecules on their surface, namely, co-stimulation 
molecules and co-inhibition molecules. The process 
which T cells exert an immune response involves being 
activated first by antigen recognition signal, and then 
fine-regulating T cell response by co-stimulating signal 
molecules. The co-inhibition molecules that play a 
negative immune regulatory role are also called immune 
checkpoint molecules. Common checkpoint proteins in 
tumor immunotherapy include PD-1, CTLA-4, T cell 
immunoglobulin and Mucin Domain 3(TIM-3), LAG 3, 
T cell immunoglobulin and ITIM domain (TIGIT), etc. 
Among which the PD-1 and CTLA-4 are most focused 
due to apparent effectiveness of their functions in 
treatment of malignant tumors.
3. Biological Characteristics of PD-1 and Its 
Ligand
A member of the CD28 superfamily, PD-1, was originally 
cloned from apoptotic small T cell hybridoma 2B4.11 and 
is the immunoglobulin superfamily Type I transmembrane 
glycoprotein. It is mainly expressed on the surface of 
activated T lymphocytes, NK cells, monocytes and B 
lymphocytes. As an important immune checkpoint for 
immunosuppression of tumor-infiltrating T cells, PD-1 
is up-regulated in a variety of tumor microenvironments, 
such as gastric cancer, ovarian cancer, pancreatic cancer, 
hematologic tumors, etc. PD-1 exists as monomer on 
the cell surface and is composed of an extracellular IgV 
region, a transmembrane domain, and an intracellular 
tail [5]. There are four N-ligand glycosylation sites in 
the extracellular immunoglobulin - like domain for 
binding to ligands. There are two tyrosine residues in the 
intracellular area: the terminal N is the immunoreceptor 
tyrosine-based inhibitory motif (ITIM), and the terminal 
C is immunoreceptor tyrosine switch motif (ITSM).
PD-1 receptor has two ligands: PD-L1 (CD274/ B7-
H1) and PD-L2 (CD273/B7-DC). PD-L1 has a wider 
expression spectrum than PD-L2, and is mainly expressed 
in hematopoietic and non-hematopoietic cells (including 
epithelial cells, vascular epithelial cells, stromal cells, 
etc.). Under the action of inflammatory factors (including 
type I and type II interferon, TNF-α and VEGF) or tumor 
cells, PD-L1 is induced to be expressed in stromal cells 
and tumor cell surfaces of tumor tissues. PD-L1 is highly 
expressed in many solid tumors, such as non-small cell 
lung cancer, melanoma, prostate cancer, breast cancer, re-
nal cell carcinoma, etc [6-7], also in HNSCC.
Current studies have shown that PD-1 binding with 
ligands blocks the activation of T cells and thus blocks 
their proliferation through the following pathways, to 
make the T cell immune response incompetent: First, 
in the case of simultaneous mating with T cell receptor 
(TCR), the phosphatase SHP-2 with the SH2 domain 
is recruited by the intracellular ITSM to block the 
phosphorylation mediated by the activation of TCR 
molecules. This prevents T cell activation and cytokine 
production. Secondly, the combination of PD-1 and 
PD-L1 can inhibit the activation of CD28-mediated 
phosphoinositide-3-kinase (PI3K), dephosphorylate the 
phosphatidylinositol 3-kinase B -protein kinase B (PI3K-
AKT), and thus inhibit T cell activation. This inhibitory 
effect of PD-1 can be reversed by enhanced CD28 or 
signal transduction and activator of transcription (STAT) 
cytokines.
Based on the mechanism described above, PD-1 
inhibitors, and PD-1 ligand PD-L1 inhibitors, block the 
interaction between PD-1 and PD-L1, thereby blocking 
the immune escape of tumors. Blocking the PD-1/PD-
L1 signaling pathway has achieved a relatively long-
lasting anti-cancer response. With breakthrough progress 
of efficacy on the treatment of various malignant tumors 
such as melanoma, non-small cell lung cancer, Hodgkin’s 
lymphoma, genitourinary system tumors, colorectal 
cancer, etc., PD-1 inhibitors continues to expand its tumor 
DOI: https://doi.org/10.30564/jor.v2i2.2429
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treatment spectrum [8].
PD-L2 and PD-L1 share 37.4% homology at the gene 
level. PD-L2 mainly involves in regulating the immune 
response caused by natural environmental antigens. The 
expression and regulation mechanisms of PD-L1 and PD-
L2 are different. Previous studies have shown that PD-
L2 is mainly expressed in dendritic cells, monocytes, 
mast cells derived from bone marrow, and B cells in the 
germinal center. Also, it’s slightly expressed in vascular 
endothelium and T cells. Recent studies have used 
innovative immunohistochemical methods to analyze 
more than 400 tissue samples involving 7 different types 
of tumors, including renal cell carcinoma, bladder cancer, 
melanoma, non-small cell lung cancer, triple negative 
breast cancer, gastric cancer, and HNSCC. The results 
showed that there was no PD-L2 expression in the tumor 
cells of renal cell carcinoma tissue samples; very few 
tumor cells expressed PD-L2 in melanoma samples; the 
expression level of PD-L2 was significantly increased in 
gastric cancer and triple-negative breast cancer;  and more 
than half of tumor cells overexpress PD-L2 in HSNCC 
tissue samples [9].
4. PD-1 and Its Ligand: Their Expression in 
OSCC and Anti-Tumor Efficacy 
As the main ligand of PD-1, PD-L1 is not only overexpressed 
on the surface of t，umor cells in OSCC, but also 
expressed on the surface of immune cells in the tumor 
microenvironment, including regulatory T cells (Tregs), 
natural killer (NK) cells and Antigen presenting cells 
(APCs) [10-12]. Previous studies showed that the expression 
of PD-1 and PD-L1 on the surface of CD4+ and CD8+ 
T cells in the peripheral blood of OSCC patients was 
significantly higher than that of the control group; also, the 
study found that the level of soluble PD-1 in the plasma 
of OSCC patients was also significantly higher than the 
control group [13]. In addition, the expression of PD-1 
in the peripheral blood of patients with OSCC or with 
precancerous lesions of actinic cheilitis (AC), is higher 
than that of normal people, while the expression of PD-1 
on CD4+ and CD8+ T cells in the tumor site of OSCC 
patients was higher than that of the AC ones [14]. Another 
study showed that compared with normal oral mucosa, the 
expression of PD-L1 in OSCC is significantly up-regulated, 
and such expression of PD-L1 in peripheral blood of 
patients with lymph node metastasis is significantly higher 
than that of patients without lymph node metastasis. 
Research suggests that in addition to the local area of the 
tumor, the expression of immune checkpoints in the entire 
system should also be considered [15].
The correlation between the expression or threshold 
of PD-1 ligand and the anti-tumor immune efficacy of 
PD-1 immune checkpoint inhibitors remains unclear. 
Reviewing the approved clinical trials of PD-1/PD-L1 
drugs, the current expression of PD-L1 is basically an 
item for mandatory check. Known results suggest that 
to most cancers approved to be treated with immune 
checkpoint inhibitors, such as non-small cell lung cancer, 
melanoma, urothelial carcinoma, OSCC (HNSCC), 
etc., PD-L1 expression is positively correlated with the 
objective response rate and/or survival time [16]. It is 
currently believed that the expression of PD-L1 in tumor 
cells exceeding 10% is related to a poor prognosis, and 
it is generally regarded as a demarcation point related 
to clinical efficacy. Related studies showed that the PD-
L1 expression rate of OSCC samples is 10% to 15%, 
which is negatively correlated with tobacco and alcohol 
consumption, and PD-L1 expression is correlated with 
tumor recurrence and survival rate [17]. However, there 
are still some defects of PD-L1 expression in clinical 
applications: (1) The expression of PD-L1 in some tumors 
(such as renal cell carcinoma) has no correlation with 
clinical benefit; (2) Even in the same type of tumor, the 
relationship between the expression of PD-L1 and the 
efficacy may be contrary to the prediction [18]. 
There are few studies on the correlation between PD-
L2 and PD-1 immune checkpoint inhibitors in anti-
tumor efficacy. Current researches suggest that PD-
L2 is overexpressed on the surface of OSCC tumor 
cells. Jennifer Yearley’s study showed that among 172 
patients with relapsed or metastatic HNSCC treated with 
pembrolizumab, the ORR of patients with PD-L1 and PD-
L2 expression both positive was 27.5%, while the ORR of 
patients with positive PD-L1 expression and negative PD-
L2 expression was only 11.4%.Therefore, the expression 
level of PD-L2 can be used as supplementary information, 
together with the expression level of PD-L1, as predictors 
of tumor efficacy [5]. This emphasizes the importance 
of PD-L2 expression, which is conducive to a better 
understanding of the tumor biological significance of 
PD-1 signaling pathway.
5. Application of PD-1/PD-L1 Checkpoint In-
hibitors in OSCC Treatment
Since the second half of 2016, nivolumab and pembrolizumab 
have been approved by FDA for the treatment of oral 
cancer. Pembrolizumab, also known as MK-3475, is the 
first PD-1 monoclonal antibody approved for clinical trials 
of recurrent/metastatic HNSCC. Among the 132 patients 
in the experimental group of the multicenter phase I 
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clinical trial (KEYNOTE-012), 49.3% of them obtained 
partial response or stable disease, of which 78% were PD-
L1 positive patients, the response rate of PD-L1 positive 
patients was 20%, and 86% of patients showed a durable 
response. The patients who received a response after 
treatment in this study included HPV+ patients as well 
as HPV- patients. Research showed a low incidence of 
adverse drug reactions, with only 7.6% of patients with> 
grade 3 drug-related adverse reactions [19].
Pembrolizumab has shown anti-tumor activity and 
controllable drug toxicity in early trials. The phase III 
clinical study KEYNOTE-040 further observes its efficacy 
and safety. From December 24, 2014 to May 13, 2016, 247 
patients were randomly assigned to the pembrolizumab 
group, and other 248 patients were randomly assigned to 
the standard chemotherapy group. As of May 15, 2017, 
181 (73%) patients in the pembrolizumab group and 207 
(83%) patients in the standard treatment group had died. 
The median overall survival of the pembrolizumab group 
and standard treatment group was 8.4 months vs. 6.9 
months respectively; and the overall incidence of> grade 
3 drug-related adverse reactions in the pembrolizumab 
group was lower (33 cases [13%] vs 85 cases [36%]). 
The most common treatment-related adverse events of 
pembrolizumab were hypothyroidism (33 cases [13%] 
patients) and fatigue (43 cases [18%]) [20]. Another phase 
III clinical study (KEYNOTE-048) was made based on 
platinum-resistant HNSCC patients with relapse and 
metastasis, its intermediate study results were announced 
in 2018 by the European Society of Medical Oncology 
(ESMO): Compared with the standard chemotherapy 
regimen EXTREME (PFE: carboplatin/cisplatin, 
5-FU, cetuximab + cetuximab maintenance), among 
the 882 patients who used pembrolizumab as the first-
line treatment，the combined positive score of PD-L1 
expression (CPS. The number of PD-L1 positive cells 
in tumor cells, lymphocytes, and macrophages) was ≥20 
with an OS rate of 39%, while OS was only 22% in the 
group of patients CPS ≥1.
I n  t he  mu l t i c en t e r  phase  I I I  c l i n i ca l  s t udy 
(CHECKMATE-141) of Nivolumab for the treatment of 
platinum-resistant recurrent or metastatic HNSCC, the 
overall survival of patients receiving nivolumab (240 
cases) and docetaxel treatment were 7.5 vs 5.1 months 
respectively. The 1-year overall survival rate was 36.0% 
vs 16.6%, and the study showed that in nivolumab 
treatment, the overall incidence of drug-related adverse 
reactions of >3 grade was lower (13.3% vs 35.1%) [22]. 
Based on the above research data, in November 2016, the 
FDA approved nivolumab for the treatment of patients 
with recurrent or metastatic HNSCC [22].To observe the 
long-term efficacy and safety of the drug on PD-L1-
expressing patients, a preliminary analysis with 2-year 
follow-up was made and it showed that Nivolumab can 
significantly improve OS and maintain controllable 
and consistent safety. But at the same time studies also 
showed that OS has no correlation with PD-L1 expression 
and HPV infection status. However, in the treatment 
of Pembrolizumab, the results of KEYNOTE-040 and 
KEYNOTE-048 support that PD-L1+ can significantly 
improve the survival time of patients.
In the phase I clinical trial of HNSCC, PD-L1 antibody 
also showed a certain degree of clinical efficacy. Currently, 
representative antibodies targeting PD-L1 include 
durvalumab (MEDI-4736), atezolizumab (MPDL3280A) 
and BMS-936559 (MDX1105), which have been used 
as monotherapy or in combination with other drugs in 
clinical trials of multiple tumors [23]. The durvalumab (IgG1 
isotype) study recruited 62 patients with R/M HNSCC. 
The results of the study showed an ORR of 12%, and a 
sustained response time of 4 to 43 weeks was obtained. 
The response rate of PD-L1 positive patients was 25%. 
The 24-week disease control rate of all patients was 16%, 
which was 25% of PD-L1 positive patients [24]. In addition, 
there are randomized phase I/II clinical trials evaluating 
durvalumab combined with AZD9150 or AZD5069 
(NCT02499328) for patients with metastatic HNSCC. The 
study is currently evaluating clinical safety, efficacy and 
ORR [26]. There are few studies on Atezolizumab in the 
treatment of HNSCC. According to the clinical deadline 
of April 30, 2013, a study included a total of 277 patients 
with advanced cancer, with a response rate (RR) about 
17%, but the number of HNSCC was small (n = 6) [26]. 
Currently in clinical trials of HNSCC, PD-L1 antibody 
is combined with other immune checkpoint inhibitors to 
improve efficacy. Some trials evaluating the combination 
of durvalumab monotherapy and tremelimumab (anti-
CTLA-4) are ongoing (NCT02551159, NCT02369874, 
NCT02319044), and the clinical results of such 
immunotherapy combinations are highly anticipated [27,28].
6. Problems and Challenges of PD-1 Immune 
Checkpoint Inhibitors in OSCC Treatment
PD-1 immune checkpoint inhibitors currently have 
achieved good clinical effects in the treatment of HNSCC 
and other malignant tumors, but only a small number 
of patients can benefit from monotherapy. Therefore, in 
order to improve the disease response rate and long-term 
efficacy, some preclinical studies and clinical trials have 
used PD-1 combined with radiotherapy, radiotherapy, 
targeted drugs and other immune checkpoint inhibitors for 
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the treatment of HNSCC, and achieved varying degrees 
of clinical efficacy initially. Such as Pembrolizumab 
combined with cetuximab in the treatment of HNSCC 
(NCT02586207) [29]. Pembrolizumab combined with 
platinum drugs or radiotherapy is used for neoadjuvant 
treatment of HNSCC surgery, exploring the use of 
pembrolizumab for resectable HPV-negative, and 
neoadjuvant and/or postoperative adjuvant treatment of 
patients with stage III/IV HNSCC [30-31].
Although a number of trials have confirmed the 
effectiveness and the short-term safety of anti-PD-1/PD-L1 
pathway in the treatment of tumors, preliminary clinical 
research data showed that patients with different types of 
malignant tumors, including OSCC patients, have primary 
resistance to PD-1/PD-L1 drugs as high as 60%, therefore, 
it is urgent to further improve the treatment response 
rate and long-term efficacy [32]. Since the PD-1/PD-L 
pathway plays an important role in autoimmune regulation 
and tumor immunity, with the complexity of the tumor 
microenvironment, the primary drug resistance mechanism 
of PD-1 antibodies is also complicated. The current 
research on the resistance mechanism of PD-1 antibodies 
mainly proposes the following points: weak tumor cell 
immunogenicity, limited immune cell infiltration within 
the tumor, tumor burden factors, different mismatch 
repair(dMMR) in solid tumors, and multiple expressions 
in the tumor microenvironment(TME) inhibitory receptors 
and pathways of immunosuppression induced by TME, 
etc. [33-35].
In response to the problem of resistance to PD-1 
immune checkpoint inhibitors in the treatment of OSCC, 
besides improving the efficacy through combination with 
other treatments, researchers are also actively exploring 
resistance mechanisms and other solutions. Finding 
biomarkers for predicting efficacy is an effective way 
to achieve precision treatment of OSCC. Most current 
studies believe that PD-1/PD-L1 inhibitors have higher 
benefits for patients with PD-L1 positive tumors. Based 
on the current research results, it is still uncertain whether 
the effective rate of PD-1 inhibitors in the treatment of 
OSCC will be affected by the expression level of tumor 
PD-L1. Based on the current studies, there is currently 
no evidence that HPV infection is directly related to the 
effective rate of PD-1 inhibitors and the durable response 
rate of patient [36]. The expression level of PD-L2 can be 
used as supplementary information, combined with the 
expression of PD-L1 to be a predictor of efficacy. 
In addition, the composition of the digestive tract 
microbial population is related to immune disorders and 
the occurrence and development of many malignant 
tumors. Two retrospective clinical studies emphasized 
that the application of antibiotics will affect the efficacy 
of immunotherapy, and proposed that to the patients with 
advanced tumors suppress immune checkpoints, their 
drug resistance (especially the PD-1/PD-L1 antibody) 
can be caused by the abnormal composition of intestinal 
microbes [37-38]. OSCC originates from the oral mucosal 
epithelium, and the oral microbiota is often exposed to 
external environmental factors. Compared with healthy 
controls, OSCC patients have a different microbiota 
composition in saliva, and the presence of specific bacteria 
is associated with the risk of OSCC. Current studies also 
found that the composition of the microbial population is 
related to the expression of HPV. The correlation between 
the composition of oral microbes and the resistance 
of immune checkpoint inhibitors needs to be further 
confirmed [39].
Immune checkpoint inhibitors have opened a new 
era of tumor immunotherapy, and PD-1 inhibitors have 
an important role in promoting the efficacy of OSCC 
treatment. However, the drug currently also faces a 
series of problems in clinical application, including 
clinical efficacy and immunotherapy-related side effects. 
To solve these problems, the researchers still have a long 
way to go.
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